First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FL115 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumors
Latest Information Update: 03 Jul 2025
At a glance
- Drugs FL 115 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Suzhou Forlong Biotechnology
Most Recent Events
- 26 Jun 2025 Planned End Date changed from 30 Sep 2025 to 30 Sep 2026.
- 26 Jun 2025 Planned primary completion date changed from 15 May 2025 to 30 Sep 2026.
- 25 Jul 2024 Status changed to recruiting.